Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Epidemiology and eligible population inputs
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Economic information and modeling report Budget impact model

Epidemiology and eligible population inputs

1 evidence topic · 1 source

Eligible population and annual transplantation assumptions

Input	Quoted value
Eligible patients estimated by clinical experts	“20”
Annual imlifidase-enabled transplants	“4 to 5”